FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for FILSPARI (sparsentan) submitted by Travere Therapeutics, Inc., relating to changes or expansion of the product's lab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Iga Nephropathy

Drugs mentioned

• FILSPARI (SPARSENTAN)

Snippet

SUPPL AP for FILSPARI (SPARSENTAN)